Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981720 · ClinicalTrials.gov registry record · Phase 1
Extension Study of PRX-102 for up to 60 Months
A Phase 1 study, sponsored by Protalix.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01981720 is a Phase 1 study that has completed, run by Protalix. The registered enrollment target is 15 participants.
The verdict
NCT01981720, a Phase 1 study, has completed, sponsored by Protalix.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
Interventions
- BIOLOGICAL PRX-102 (pegunigalsidase alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-01-16 |
| Est. Completion | 2021-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981720
The ClinicalTrials.gov registry entry for NCT01981720 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protalix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRX-102 (pegunigalsidase alfa) is the first listed.
NCT01981720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981720 about?
NCT01981720 is a clinical study titled "Extension Study of PRX-102 for up to 60 Months". To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
What is the current status of trial NCT01981720?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-01-16. Estimated completion is 2021-11-09.
What interventions are being tested in trial NCT01981720?
The interventions under investigation include: PRX-102 (pegunigalsidase alfa) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01981720?
This trial is sponsored by Protalix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.